CompletedNot Applicable

Pulmonary Artery Pressure in COVID-19 Survivors

Egypt15 participantsStarted 2022-04-01

Plain-language summary

Post COVID-19 pulmonary hypertension can develop as a result of lung parenchymal damage and altered pulmonary circulation induced by COVID-19 infection. It has been proposed that this type of PH should be considered a combination between PH of group 3 (due to interstitial fibrosis and alveolar inflammation) and 4 (induced by thrombotic/thromboembolic processes, endothelial injury, or, at least, hypoxic vasoconstriction). Right heart catheterization (RHC) is the gold standard for assessing pulmonary hemodynamics and is mandatory for confirming the diagnosis of pulmonary hypertension (PH), assessing the severity of hemodynamic impairment, and performing vasoreactivity testing in selected patients

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * COVID-19 survivors from a moderate/severe COVID-19 pulmonary infection according to WHO COVID-19 clinical severity classification , ≥ 18 years, with residual symptoms and signs suggestive of pulmonary hypertension and not explained by other condition. Exclusion Criteria: * Previous diseases that could explain the existence of PH e.g. cardiovascular, pulmonary diseases or history of pulmonary thromboembolism. * Hemodynamic instability. * Absolute contraindications to RHC placement include: * Infection at the insertion site. * The presence of a right ventricular assist device. * Insertion during cardiopulmonary bypass. * Lack of consent. * Relative contraindications to RHC placement include: * Coagulopathy (INR \>1.5), thrombocytopenia (platelet count \<50,000/microL). * Electrolyte disturbances. * Severe acid-base disturbances.

What they're measuring

Assessment of pulmonary artery pressure in COVID-19 survivors using right heart catheterization (RHC)

Timeframe: 1.5 year

Trial details

NCT IDNCT05993338

SponsorMansoura University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-04-01